(Q44627113)

4 December 2017

Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk (English)

1 reference

4 December 2017

1 reference

4

James P Wilson

1 reference

4 December 2017

Stephen P Motsko

1

1 reference

4 December 2017

Karen L Rascati

2

1 reference

4 December 2017

Anthony J Busti

3

1 reference

4 December 2017

Jamie C Barner

5

1 reference

4 December 2017

Kenneth A Lawson

6

1 reference

4 December 2017

Jason Worchel

7

1 reference

4 December 2017

1 January 2006

1 reference

4 December 2017

1 reference

4 December 2017

29

1 reference

4 December 2017

7

1 reference

4 December 2017

621-632

1 reference

https://scigraph.springernature.com/pub.10.2165/00002018-200629070-00007

4 December 2017

0 references

cites work

Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs

1 reference

12 December 2020

The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults

1 reference

12 December 2020

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

1 reference

12 December 2020

Where do elderly veterans obtain care for acute myocardial infarction: Department of Veterans Affairs or Medicare?

1 reference

12 December 2020

Positive predictive value of the diagnosis of acute myocardial infarction in an administrative database

1 reference

12 December 2020

Cardiovascular events associated with long-term use of celecoxib, rofecoxib and meloxicam in Taiwan: an observational study.

1 reference

12 December 2020

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

1 reference

12 December 2020

Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery

1 reference

12 December 2020

Incidence of thrombotic cardiovascular events in patients taking celecoxib compared with those taking rofecoxib: interim results from the New Zealand Intensive Medicines Monitoring Programme

1 reference

12 December 2020

COX-2 and beyond: Approaches to prostaglandin inhibition in human disease

1 reference

12 December 2020

Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs

1 reference

12 December 2020

Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2.

1 reference

12 December 2020

Expression of COX-1 and COX-2 mRNAs in atherosclerotic plaques

1 reference

12 December 2020

Risk of cardiovascular events and rofecoxib: cumulative meta-analysis

1 reference

12 December 2020

Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis

1 reference

12 December 2020

Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib

1 reference

12 December 2020

Cyclooxygenase-2--specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients

1 reference

12 December 2020

A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin

1 reference

12 December 2020

A comparison of reported gastrointestinal and thromboembolic events between rofecoxib and celecoxib using observational data

1 reference

12 December 2020

Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults

1 reference

12 December 2020

Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study

1 reference

12 December 2020

Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis.

1 reference

12 December 2020

Stroke: who's counting what?

1 reference

12 December 2020

COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease

1 reference

12 December 2020

Do some inhibitors of COX-2 increase the risk of thromboembolic events?: Linking pharmacology with pharmacoepidemiology

1 reference

12 December 2020

Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction

1 reference

12 December 2020

Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records

1 reference

12 December 2020

Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning

1 reference

12 December 2020

Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib

1 reference

12 December 2020

Selective cyclooxygenase-2 inhibition and cardiovascular effects: an observational study of a Medicaid population.

1 reference

12 December 2020

Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk

1 reference

12 December 2020

Cyclooxygenase-2 inhibition and cardiovascular events

1 reference

12 December 2020

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

1 reference

12 December 2020

Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction.

1 reference

12 December 2020

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

1 reference

12 December 2020

Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis

1 reference

12 December 2020

Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly

1 reference

12 December 2020

Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone).

1 reference

12 December 2020

Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study

1 reference

12 December 2020

10.2165/00002018-200629070-00007

Identifiers

DOI

1 reference

Dimensions Publication ID

4 December 2017

0 references

1 reference